Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: A 1-year longitudinal study

Bone

Volumn 32, Issue 4, 2003, Pages 427-433

  Montagnani, A ^a,b   Gonnelli, S ^a   Cepollaro, C ^a   Pacini, S ^a   Campagna, M S ^a   Franci, M B ^a   Lucani, B ^a   Gennari, C ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Bone mineral density; Bone turnover; Hypercholesterolemia; Osteoporosis; Statins

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; COLLAGEN TYPE 1; LIPID; PHOSPHATE; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FEMUR; FEMUR NECK; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LUMBAR SPINE; OSTEOPOROSIS; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 0037384716     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(03)00034-6     Document Type: Article

References (32)

1. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovasatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS . JAMA. 270:1998;1615-1622.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian simvastatin survival study (4S) . Lancet. 344:1994;1383-1389.
3. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. WEST of Scotland coronary prevention study group. N Engl J Med. 333:1995;1301-1307.
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
5. McFarlane S.I., Muniyappa R., Francisco R., Sowers J.R. Pleiotropic effects of statins lipid reduction and beyond . J Clin Endocrinol Metab. 87:2002;1451-1458.
6. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossigni G., Boyce B., Zhao M., Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1946-1949.
7. Garrett I.R., Esparza J., Chen D., Zhao M., Gutierrez G., Escobado A., Horn D., Mundy G.R. Statins mediate their effects on osteoblasts by inhibition of HMG-CoA reductase and ultimately BMP-2. J Bone Miner Res. 15:(Suppl.1):2000;S225. [Abstract].
8. Maeda T., Matsunuma A., Kawane T., Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun. 280:2001;874-877.
9. Ohnaka K., Shimoda S., Nawata H., Shimokawa H., Kaibuchi K., Iwamoto Y., Takayanagi R. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun. 287:2001;337-342.
10. Sugiyama M., Kodama K., Konishi K., Abe K., Oikawa S. Compactin and simvastatina, but not pravastatin, induce bone morphogenetic protein 2 in human osteosarcoma cells. Biochem Biophys Res Commun. 271:2000;688-692.
11. van Beek E.J., Reekers J.A. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 264:1999;108-111.
12. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., Wesolowski G., Russell R.G., Rodan G.A., Reszka A.A. Alendronate mechanism of action geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro . Proc Natl Acad Sci USA. 96:1999;133-138.
13. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational of GTP-binding proteins, including Ras. J Bone Miner Res. 13:1998;581-589.
14. Bauer D.C., Mundy G.R., Jamal S.A., Black D.M., Cauley J.A., Harris F., Duong T., Cummings S.R. Statin use, bone mass and fracture an analysis of two prospective studies . J Bone Miner Res. 14:(Suppl.1):1999;S179. [Abstract].
15. Chan K.A., Andrade S.E., Boles M., Buist D.S.M., Chase G.A., Donahue J.G., Goodman M.J., Gurwitz J.H., LaCroix A.Z., Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 355:2000;2185-2188.
16. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 283:2000;3205-3210.
17. Wang P.S., Solomon D.H., Mogun H., Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 283:2000;3211-3216.
18. Reid I.R., Hague W.H., Emberson J., Baker J., Tonkin A., Hunt D., Mac Mahon S., Sharpe N. Effect of pravastatin on frequency of fracture in the LIPID study secondary analysis of a randomised controlled trial . Lancet. 357:2001;509-512.
19. Coons J.C. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann Pharmacother. 32:2002;326-330.
20. Kanis J.A., Johnell O., Oden A., Jonsson B., De Laet C., Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone. 27:2000;585-590.
21. Chung Y.S., Lee M.D., Lee S.K., Kim H.M., Fitzpatrick L.A. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab. 85:2000;1137-1142.
22. Wada Y., Nakamura Y., Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med. 160:2000;2865.
23. Pasco J.A., Kotowicz M.A., Henry M.J., Sanders K.M., Nicholson G.C. Geelog Osteoporosis Study. Statin use, bone mineral density, and fracture risk Geelog osteoporosis study . Arch Intern Med. 162:2002;537-540.
24. Bjarnason N.H., Riis B.J., Christiansen C. The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int. 12:2001;380-384.
25. Stein E.A., Farnier M., Waldstreicher J., Mercuri M. Effects of statins on biomarker of bone metabolism a randomised trial . Nutr Metab Cardiovasc Dis. 11:2001;84-87.
26. Chan M.H., Mak W.L., Chiu R.W., Chow C.C., Chan I.S., Lam C.K. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab. 86:2001;4556-4559.
27. Rogers M.G., Watts D.J., Russel R.G. Overview on bisphosphonates. Cancer. 80:(Suppl.8):1997;1652-1660.
28. Martiz F.J., Conradie M.M., Hulley P.A., Hough F.S. The effects of statins on bone mineral density and quantitative bone histomorphometry in rodents. Osteoporosis Int. 13:2002;S12. [Abstract].
29. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E. Randomised trials of effect of alendronate on risk of fracture in women with existing vertebral fractures fracture intervention trial research group . Lancet. 348:1996;1535-1541.
30. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., Lund B., Ethgen D., Pack S., Roumagnac I., Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osterporos Int. 11:2000;83-91.
31. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Gluer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators . JAMA. 282:1999;637-645.
32. Chesnut C.H. 3rd, Silverman S., Andriano K., Genant H., Gimona A., Harris S., Kiel D., LeBoff M., Maricic M., Miller P., Moniz C., Peacock M., Richardson P., Watts N., Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis the prevent recurrence of osteoporotic fractures study PROOF study group . Am J Med. 109:2000;330-331.